Navigation Links
Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test

PROVO, Utah, July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader in genome annotation and interpretation, today announced an agreement with Lineagen, Inc., to provide next-generation sequencing (NGS) analytics for Lineagen's NextStepDx PLUS.  Lineagen, focused on the diagnostic evaluation of neurodevelopmental and neurological disorders, currently offers FirstStepDx PLUS, a customized chromosomal microarray (CMA) testing service used by healthcare providers as a first-line genetic diagnostic test for individuals with developmental delay (DD), autism spectrum disorders (ASD) and other disorders of childhood development.  Later this year, the Company anticipates launching NextStepDx PLUS, a next-generation sequence-based test that is specifically designed to increase the clinical detection of single nucleotide genetic variants linked to ASD and other disorders of childhood development. ASD is the fastest-growing neurodevelopmental disability in the U.S., affecting approximately 1 in 88 children, including up to 1 in 58 boys.

"Tute Genomics' NGS analysis platform can rapidly and accurately analyze complex whole exome data and generate customized clinical reports, and we are very pleased to partner with Tute as we prepare to launch NextStepDx PLUS later this year," commented Michael Paul, Ph.D., CEO of Lineagen.  "Our new test identifies previously unknown genetic variants that confer a genetic risk of developing ASD, which Lineagen validated along with The Children's Hospital of Philadelphia and the University of Utah.  Together, Lineagen's FirstStepDx PLUS and NextStepDx PLUS genetic testing service are expected to deliver the highest clinical detection rate clinically available for ASD and other disorders of childhood development."

Reid Robison, M.D., M.B.A., CEO of Tute Genomics, said, "This new partnership between Lineagen and Tute will accelerate progress in this area, bringing help and answers to families and leading to increased scientific understanding of the neurobiology of Autism as a necessary step towards treatments."

ASD Expertise of the Tute Genomics Team

Tute Genomics' leadership team possesses leading expertise in ASD discovery.  As a former researcher at the University of Utah, Dr. Robison conducted gene-finding studies in large extended pedigrees with ASD. He also has also been principal investigator for a number of early-stage clinical trials of novel therapeutics for ASD. 

Kai Wang, Ph.D., President of Tute Genomics, has researched extensively the genetics of ASD and related psychiatric disorders. Dr. Wang led or participated in multiple copy number variation studies, genome-wide association studies and next-generation sequencing studies on ASD. His study on common genetic variants associated with ASD, featured in a May 2009 issue of the journalNature, was named one of Time magazine's Top 10 Medical Breakthroughs of 2009. 

About Tute Genomics

Tute Genomics offers innovative cloud-based solutions to accelerate genetic discovery and enable precision medicine. Tute developed a clinical genome interpretation platform that assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Given sequencing data from whole genomes or panels of genes, Tute returns over 125 annotations on variants and genes, performs family-based and case/control analyses to identify causal disease genes, and generates clinical reports for clinicians to focus on clinically relevant and actionable findings. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation & interpretation technology with over 750 scientific publications. The genome revolution is here, and Tute envisions a future where clinical reports on genomes are interactive and integrated into medical records, and aims to be the "dropbox of genomes" for clinicians and patients alike. To learn more please visit

About Lineagen

Based in Salt Lake City, Utah, Lineagen's mission is to accelerate and enhance the diagnostic evaluation of medical conditions so that the best possible outcomes can be achieved for patients and their families.  Our first commercial offering, FirstStepDx PLUS, provides physicians with a fully integrated genetic testing, counseling, and developmental screening service to aid in the diagnostic evaluation of individuals with ASD or other disorders of childhood development.  In addition to our deep commitment to ASD and developmental delay, we have ongoing scientific programs in the areas of multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD). For additional information, please visit

About FirstStepDx PLUS

Lineagen's FirstStepDx PLUS and related autism-risk screening services ( have been developed with the specific intention of helping physicians, patients, and families navigate the diagnostic "odyssey" of individuals with ASD and other disorders of childhood development.  Chromosomal microarray (CMA) genetic testing is medically recommended for individuals with ASD and other disorders of childhood development so that a genetic cause in these individuals can be identified earlier and more efficiently.  The FirstStepDx PLUS test includes genetic counseling, the most advanced, customized CMA clinically available, and a detailed, personalized report created specifically for each individual tested.  FirstStepDx PLUS is specifically designed to help parents, physicians, and other healthcare providers significantly shorten the time to clinical action, allowing access to proven clinical management and treatment approaches as early as possible.  The customized and proprietary CMA platform incorporated into FirstStepDx PLUS was developed in collaboration with Affymetrix under the Powered by Affymetrix program.  Lineagen's FirstStepDx PLUS and NextStepDx PLUS incorporate novel copy number and single nucleotide genetic variants that were validated in a 9,000-person genetic study by researchers affiliated with The Children's Hospital of Philadelphia (CHOP), the University of Utah, Golden Helix, Inc, and Lineagen ( and

The FirstStepDx PLUS genetic test was the first such test to be available as a fast and painless cheek swab (FirstStepDx PLUS Buccal), eliminating the need for a blood draw.  For more information about FirstStepDx PLUS, please call Lineagen at 888-888-OPEN (888-888-6736) or visit

Media Contact: Reid J. Robison, M.D. M.B.A., CEO, Tute Genomics, (858) 779-4363,

News distributed by PR Newswire iReach:

SOURCE Tute Genomics
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Tute Genomics Raises $1.5M for Cloud-based Genome Analytics & Machine-learning for Gene Discovery
2. Rubicon Genomics Reports Surge In 2013 Sales Of Its Nucleic Acid Library Prep Kits
3. Rubicon Genomics Expands Distribution in Europe and Asia
4. Catching up with the Genomic Era in Oncology: Key Considerations for Incorporating Genomics into Oncology Drug Development, a New and Upcoming Webinar Hosted by Xtalks
5. Tute Genomics appoints Dr. Mingfu Zhu as Director of Bioinformatics
6. BioNano Genomics Announces the Adoption of Irys System by the Garvan Institute of Medical Research
7. Biogas Consortium Using Genedata Selector for Metagenomics-based Process Optimization
8. Healthcare VC Dr. Dinesh Patel to serve on Tute Genomics Board of Directors
9. Tute Genomics Launches at 2013 ASHG Conference
10. BioNano Genomics Announces The Purchase Of The Irys System By The Chinese Academy Of Sciences And Tel Aviv University
11. NextCODE Health Launches Operations with Exclusive License to Leverage deCODE genetics Genomics Platform for Sequence-Based Clinical Diagnostics, and $15 Million in Venture Financing
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... ... 24, 2015 , ... This fall, global software solutions leader SAP and AdVenture ... develop and pitch their BIG ideas to improve health and wellness in their schools. ... to win the title of SAP's Teen Innovator, an all-expenses paid trip to Super ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... LAVAL, QC , Nov. 24, 2015 /CNW Telbec/ - ... the "Corporation") announced today that Mr. Pierre Laurin , ... a corporate presentation at the upcoming Piper Jaffray 27 th ... York Palace Hotel, on December 1-2, 2015. ... be available for one-on-one meetings throughout the day. The presentation ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/22/2015)... BEDFORD, Mass., Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ... financial results for its third quarter ended September 30, 2015.  ... third quarter of 2015 was $4.0 million, a decrease of 33% ... income in the third quarter of 2015 was $2.2 million, or ... per diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):